Limitations of 6-minute Walk Test Reference Values for Spinal Muscular Atrophy

Overview

Journal Muscle Nerve

Date 2019 Dec 30

PMID 31884700

Citations 3

Authors

Ashley M Goodwin

Kayla M D Cornett

Marnee J McKay

Joshua Burns

Carol Ewing Garber

Darryl C De Vivo

Jacqueline Montes

Affiliations

Soon will be listed here.

Abstract

Introduction: The 6-minute walk test (6MWT) is a well-established clinical assessment of functional endurance, validated as a measure of walking ability in spinal muscular atrophy (SMA). The current availability of disease-modifying therapies for SMA indicates a growing need for normative reference data to compare SMA patients with healthy controls.

Methods: The literature was searched in two scientific databases. Studies were evaluated and selected based on adherence to American Thoracic Society guidelines for administering the 6MWT. Reference equations from the selected studies were applied to 6MWT data collected from SMA patients to calculate and compare % predicted values.

Results: Three pediatric and six adult studies were selected for comparison. The % predicted values using the pediatric and adult equations ranged from 47.7 ± 18.2% to 67.6 ± 26.2% and 43.0 ± 17.9% to 59.5 ± 26.2%, respectively, and were significantly different (P < 0.001).

Discussion: Results suggest significant variability between % predicted values derived from published reference equations in children and adults, despite adherence to 6MWT standardization.

Citing Articles

Changes in real-world walking speed following 60-day bed-rest.

Grassi M, Von Der Straten F, Pearce C, Lee J, Mider M, Mittag U NPJ Microgravity. 2024; 10(1):6.

PMID: 38216584 PMC: 10786829. DOI: 10.1038/s41526-023-00342-8.

Natural history of 10-meter walk/run test performance in spinal muscular atrophy: A longitudinal analysis.

Krosschell K, Townsend E, Kiefer M, Simeone S, Zumpf K, Welty L Neuromuscul Disord. 2022; 32(2):125-134.

PMID: 35063329 PMC: 8908436. DOI: 10.1016/j.nmd.2021.08.010.

Nusinersen in pediatric and adult patients with type III spinal muscular atrophy.

Pera M, Coratti G, Bovis F, Pane M, Pasternak A, Montes J Ann Clin Transl Neurol. 2021; 8(8):1622-1634.

PMID: 34165911 PMC: 8351459. DOI: 10.1002/acn3.51411.

References

Servais L . "The Times They Are a-Changin'." In reply to El-Zaidy et al.: AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort. J Neuromuscul Dis. 2019; 6(3):319-320. DOI: 10.3233/JND-199001. View

De Vivo D, Bertini E, Swoboda K, Hwu W, Crawford T, Finkel R . Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019; 29(11):842-856. PMC: 7127286. DOI: 10.1016/j.nmd.2019.09.007. View

Oliveira A, Rodrigues C, S Rolim D, Souza A, Nascimento O, Jardim J . Six-minute walk test in healthy children: is the leg length important?. Pediatr Pulmonol. 2012; 48(9):921-6. DOI: 10.1002/ppul.22696. View

Ramanathan R, Chandrasekaran B . Reference equations for 6-min walk test in healthy Indian subjects (25-80 years). Lung India. 2014; 31(1):35-8. PMC: 3960806. DOI: 10.4103/0970-2113.125892. View

Montes J, Dunaway Young S, Mazzone E, Pasternak A, Glanzman A, Finkel R . Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy. Muscle Nerve. 2019; 60(4):409-414. PMC: 6771553. DOI: 10.1002/mus.26633. View

Salbach N, OBrien K, Brooks D, Irvin E, Martino R, Takhar P . Reference values for standardized tests of walking speed and distance: a systematic review. Gait Posture. 2014; 41(2):341-60. DOI: 10.1016/j.gaitpost.2014.10.002. View

Corey D . Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nat Neurosci. 2017; 20(4):497-499. DOI: 10.1038/nn.4508. View

Salci Y, Karanfil E, Fil Balkan A, Calik Kutukcu E, Ceren A, Ayvat F . Functional exercise capacity evaluated by timed walk tests in myasthenia gravis. Muscle Nerve. 2018; 59(2):208-212. DOI: 10.1002/mus.26345. View

Wokke J, Escolar D, Pestronk A, Jaffe K, Carter G, van den Berg L . Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve. 2008; 38(4):1236-45. DOI: 10.1002/mus.21025. View

10.

McKay M, Baldwin J, Ferreira P, Simic M, Vanicek N, Burns J . Reference values for developing responsive functional outcome measures across the lifespan. Neurology. 2017; 88(16):1512-1519. DOI: 10.1212/WNL.0000000000003847. View

11.

Holland A, Spruit M, Troosters T, Puhan M, Pepin V, Saey D . An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014; 44(6):1428-46. DOI: 10.1183/09031936.00150314. View

12.

Dourado V . [Reference Equations for the 6-Minute Walk Test in Healthy Individuals.]. Arq Bras Cardiol. 2011; . View

13.

Finkel R, Chiriboga C, Vajsar J, Day J, Montes J, De Vivo D . Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016; 388(10063):3017-3026. DOI: 10.1016/S0140-6736(16)31408-8. View

14.

de Assis Pereira Cacau L, Santana-Filho V, Maynard L, Gomes Neto M, Fernandes M, Carvalho V . Reference Values for the Six-Minute Walk Test in Healthy Children and Adolescents: a Systematic Review. Braz J Cardiovasc Surg. 2016; 31(5):381-388. PMC: 5144571. DOI: 10.5935/1678-9741.20160081. View

15.

Kraszewski J, Kay D, Stevens C, Koval C, Haser B, Ortiz V . Pilot study of population-based newborn screening for spinal muscular atrophy in New York state. Genet Med. 2018; 20(6):608-613. DOI: 10.1038/gim.2017.152. View

16.

Scoto M, Finkel R, Mercuri E, Muntoni F . Therapeutic approaches for spinal muscular atrophy (SMA). Gene Ther. 2017; 24(9):514-519. DOI: 10.1038/gt.2017.45. View

17.

Fernandes L, Mesquita A, Vadala R, Dias A . Reference Equation for Six Minute Walk Test in Healthy Western India Population. J Clin Diagn Res. 2016; 10(5):CC01-4. PMC: 4948381. DOI: 10.7860/JCDR/2016/17643.7714. View

18.

. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166(1):111-7. DOI: 10.1164/ajrccm.166.1.at1102. View

19.

GIBBONS W, Fruchter N, Sloan S, Levy R . Reference values for a multiple repetition 6-minute walk test in healthy adults older than 20 years. J Cardiopulm Rehabil. 2001; 21(2):87-93. DOI: 10.1097/00008483-200103000-00005. View

20.

Holtebekk M, Berntsen S, Rasmussen M, Jahnsen R . Physical activity and motor function in children and adolescents with neuromuscular disorders. Pediatr Phys Ther. 2013; 25(4):415-20. DOI: 10.1097/PEP.0b013e3182a635f0. View